Extended Data Fig. 10: EFHD2 (Swip1) mRNA expression correlates with a more metastatic breast cancer phenotype and Swip1 immunostaining at the plasma membrane correlates with higher death risk and metastasis incidence in TNBC.
From: Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis
(a) Analysis of Swip1 mRNA expression using qPCR in 192 breast tumours. Tumours were categorized into two groups: high EFHD2 expression (higher than the median of the entire collection) or low EFHD2 expression (lower expression than the median). The χ2-test was used for statistical analyses. EFHD2 mRNA levels based on tumour type and tumour grade are shown. (b) Validation of anti-Swip1 antibody specificity in IHC was carried out with agarose-embedded and formalin-fixed paraffin-embedded cell pellets from control- or Swip1-silenced MDA-MB-231 cells (siRNA #1 and #2). Scale bars, 50 µm. (c) Quantification of the percentage of breast cancer tumours from TNBC tissue microarray with high, medium or low Swip1 staining at the plasma membrane. (d) Kaplan–Meier plot shows overall survival of 133 triple negative breast cancer patients with high (H, red) or medium–low (M-L, blue) membranal staining of Swip1 in their tumour centre sample. The hazard ratio of high vs. medium–low Swip1 immuno-positivity was 2.34 (95% CI 1.25 to 4.41). The hazard ratios after adjustment for Ki67, 2.51 (95% CI 1.26 to 5.01); for tumour size, 2.12 (95% CI 1.08 to 4.18); for lymph node metastasis status 2.26 (95% CI 1.19 to 4.31) and for tumour grade 2.44 (95% CI 1.25 to 4.74). (e) Lymph node metastasis incidence in 130 TNBC patients from the same cohort, Fisher’s exact test p = 0.037. A higher proportion of patients with high membranal staining of Swip1 (> = 80%) had lymph node metastasis. Numerical source data are provided in Source data.
